Evaluation of an Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting

Completed · Not applicable

Conditions studied: Depression

In brief

This was a study of a genotyping tool that reported on how subjects responded to medications and could be used in a community psychiatry practice to improve medication choice for depression. After the DNA test, an interpretive report was provided to the subjects' physicians. The hypothesis of this pilot study was that it was feasible to use this pharmacogenomic algorithm in a new setting to treat depressed subjects..

Key facts

Study ID: NCT01610063
Run by: Mayo Clinic
People needed: 227
Starts: 2009-01-01
Expected to finish: 2013-05-01
Last updated by the study team: 2017-03-30

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patient is between the ages of 18 and 80.
Major depressive disorder or depressive disorder not otherwise specified as ascertained by a physician or mental health professional licensed to diagnose.
Patient is an outpatient and not in imminent need of inpatient hospitalization, or a discharging inpatient with scheduled follow-up with a Behavioral Health psychiatrist.
Patient has been referred to see a psychiatrist for optimum medication management.
Patient's Hamilton Depression Rating score is >14
Ability to read, understand and sign an informed consent document

You may not qualify if…

Serious medical illness (as ascertained via the initial triage screening process)
Patients with a diagnosis of Bipolar I disorder
Patients with a diagnosis of Schizophrenia or Schizoaffective disorder
Patients who are legally unable to consent to enrollment in the study (i.e. patients with legal guardians)

Where it is running

Franciscan Skemp HealthCare — La Crosse, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.